Graca Luis, Le Moine Alain, Cobbold Stephen P, Waldmann Herman
Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.
Immunol Res. 2003;28(3):181-91. doi: 10.1385/IR:28:3:181.
A short-treatment with nondepleting antibodies, such as those targeting CD4 or CD154 (CD40 ligand), allows long-term graft survival without the need for continuous immunosuppression. This state of immune tolerance is maintained by regulatory CD4+ T cells present within both the lymphoid tissue and the tolerated graft. The nature of such regulatory T cells, their relationship to CD4+CD25+ T cells, and their mode of action have all been the subjects of much attention recently. Here, we review recent progress on understanding the nature, specificity, and mechanisms of action of T cells mediating dominant tolerance brought about by antibody therapy.
用非耗竭性抗体进行短期治疗，如那些靶向CD4或CD154（CD40配体）的抗体，可实现长期移植物存活，而无需持续免疫抑制。这种免疫耐受状态由存在于淋巴组织和耐受移植物中的调节性CD4+ T细胞维持。这类调节性T细胞的性质、它们与CD4+CD25+ T细胞的关系及其作用方式最近都备受关注。在此，我们综述了在理解介导抗体治疗所致显性耐受的T细胞的性质、特异性和作用机制方面的最新进展。
